search
Back to results

T3AI-Pain After Breast Surgery (T3AI)

Primary Purpose

Pain, Breast Diseases

Status
Completed
Phase
Phase 3
Locations
Canada
Study Type
Interventional
Intervention
acetaminophen plus codeine
acetaminophen plus ibuprofen
Sponsored by
Nova Scotia Health Authority
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring Randomized controlled trial, Clinical trial, Breast tumor surgery, Outpatient surgery, Analgesia, Outpatient analgesia, Post surgical analgesia, ≥ 18 and ≤ 70 years of age, Elective outpatient breast surgery for:, lumpectomy/quadrantectomy +/- Sentinel Lymph Node Biopsy, lumpectomy/quadrantectomy with Axillary Node Dissection, simple mastectomy +/- Sentinel Lymph Node Biopsy, Modified Radical mastectomy

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: ages 18 to 70 inclusive outpatient breast surgery: lumpectomy; mastectomy, simple or modified; with or without sentinel lymph node biopsy, axillary node dissection. Exclusion Criteria: allergies to acetaminophen, NSAIDs, ASA or codeine. asthma. recent reported history of upper GI bleeding. daily analgesic use (OTC or opioid) pre-operatively. any opioid use in the week prior to surgery. reported history of PUD if not on PPI regularly. anticoagulant use (low dose ASA excepted). renal disease or impairment. reported history of liver disease. pregnancy. major operative complications. patients requiring admission. communication barrier. cognitive or memory impairment. reported history of drug and/or alcohol abuse.

Sites / Locations

  • QEII Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

1

2

Arm Description

Outcomes

Primary Outcome Measures

VAS Scores.
maximum VAS scores.
Likert scores.
Patient satisfaction with analgesic regimen.
Treatment failures-inadequate pain relief or inability to tolerate side effects.
Time to stopping medication.

Secondary Outcome Measures

Total Pain relief (TOTPAR).
Sum of pain intensity differences (SPID).
Amount of medication used.
Incidence of side effects.
Compliance with regimen.

Full Information

First Posted
March 2, 2006
Last Updated
January 30, 2009
Sponsor
Nova Scotia Health Authority
search

1. Study Identification

Unique Protocol Identification Number
NCT00299039
Brief Title
T3AI-Pain After Breast Surgery
Acronym
T3AI
Official Title
A Randomized Controlled Trial Comparing Combination Therapy of Acetaminophen Plus Ibuprofen Versus Tylenol #3® for the Treatment of Pain After Breast Surgery.
Study Type
Interventional

2. Study Status

Record Verification Date
September 2008
Overall Recruitment Status
Completed
Study Start Date
May 2006 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
September 2008 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Nova Scotia Health Authority

4. Oversight

5. Study Description

Brief Summary
Current standard of care for post-operative analgesia after breast surgery in CDHA is Tylenol #3® (300 mg acetaminophen, 30 mg codeine, 15 mg caffeine per tablet). We are proposing to test the analgesic efficacy of acetaminophen plus ibuprofen against Tylenol #3® in patients undergoing outpatient breast surgery.
Detailed Description
Block randomization will be used to randomize patients to one of two combinations. Group A will receive capsules containing 650 mg Acetaminophen plus 400 mg Ibuprofen. Group B will receive capsules containing 600 mg Acetaminophen, 15 mg caffeine and 60 mg codeine. Capsules are placed in identical dossettes containing a seven day supply. Patients are instructed to start taking their medications post-op and continue until they are pain free. All participants are given a series of blank Visual Analogue scales and Likert scales and instructed to record their level of pain intensity and pain relief four times per day for the entire week. Peri-operative pain management will be standardized. Patients will not receive pre-operative analgesics. Intra-operative analgesia will be intravenous opioids as selected by anaesthesiology. No local/regional anaesthesia will be used. Intravenous ketorolac will not be allowed for trial participants. All patients will receive intravenous opioid and anti-emetic if required in PACU. Any patients with peri-operative complications or other problems requiring admission or alternative analgesics will be excluded.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain, Breast Diseases
Keywords
Randomized controlled trial, Clinical trial, Breast tumor surgery, Outpatient surgery, Analgesia, Outpatient analgesia, Post surgical analgesia, ≥ 18 and ≤ 70 years of age, Elective outpatient breast surgery for:, lumpectomy/quadrantectomy +/- Sentinel Lymph Node Biopsy, lumpectomy/quadrantectomy with Axillary Node Dissection, simple mastectomy +/- Sentinel Lymph Node Biopsy, Modified Radical mastectomy

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
1
Arm Type
Active Comparator
Arm Title
2
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
acetaminophen plus codeine
Intervention Description
capsules four times daily until pain free or for a maximum of seven days
Intervention Type
Drug
Intervention Name(s)
acetaminophen plus ibuprofen
Intervention Description
capsules four times daily until pain free or for a maximum of seven days
Primary Outcome Measure Information:
Title
VAS Scores.
Time Frame
mean and daily
Title
maximum VAS scores.
Time Frame
daily
Title
Likert scores.
Time Frame
mean daily and final
Title
Patient satisfaction with analgesic regimen.
Time Frame
day 7
Title
Treatment failures-inadequate pain relief or inability to tolerate side effects.
Time Frame
daily
Title
Time to stopping medication.
Time Frame
day 7
Secondary Outcome Measure Information:
Title
Total Pain relief (TOTPAR).
Time Frame
daily
Title
Sum of pain intensity differences (SPID).
Time Frame
day7
Title
Amount of medication used.
Time Frame
day 7
Title
Incidence of side effects.
Time Frame
day 7
Title
Compliance with regimen.
Time Frame
day 7

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: ages 18 to 70 inclusive outpatient breast surgery: lumpectomy; mastectomy, simple or modified; with or without sentinel lymph node biopsy, axillary node dissection. Exclusion Criteria: allergies to acetaminophen, NSAIDs, ASA or codeine. asthma. recent reported history of upper GI bleeding. daily analgesic use (OTC or opioid) pre-operatively. any opioid use in the week prior to surgery. reported history of PUD if not on PPI regularly. anticoagulant use (low dose ASA excepted). renal disease or impairment. reported history of liver disease. pregnancy. major operative complications. patients requiring admission. communication barrier. cognitive or memory impairment. reported history of drug and/or alcohol abuse.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alex D Mitchell, MD
Organizational Affiliation
CDHA, Dalhousie University
Official's Role
Principal Investigator
Facility Information:
Facility Name
QEII Health Sciences Centre
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 2Y9
Country
Canada

12. IPD Sharing Statement

Learn more about this trial

T3AI-Pain After Breast Surgery

We'll reach out to this number within 24 hrs